Sector ratings Charles River Laboratories International, Inc. CBOE

Stocks

Market Closed - CBOE 13:44:52 2026-10-12 EDT			5-day change	1st Jan Change
300.48 ^USD	-0.49%		+3.99%	+51.24%

09:11am	Morgan Stanley Adjusts Price Target on Charles River Laboratories International to $340 From $300	MT
10-06	Charles River Laboratories International, Inc. and Autolomous Launch Apollo Orchestrate Within Charles River's Apollo Platform	CI

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Global Valuation
WUXI APPTEC CO., LTD.	70.61B		AAA
ARGENX SE	51.01B		A
LONZA GROUP AG	48.1B		AAA
IQVIA HOLDINGS INC.	42.78B		AAA
REVOLUTION MEDICINES, INC.	40.67B	-	B	-	-
BEONE MEDICINES AG	40.3B		-
CELLTRION, INC.	30.59B		A
WUXI BIOLOGICS (CAYMAN) INC.	28.16B		AAA
BIONTECH SE	24.36B	-	-	-	-
INSMED INCORPORATED	21.97B	-	BBB	-	-
GENMAB A/S	21.89B		A
MEDPACE HOLDINGS, INC.	17.08B		A
PHARMAESSENTIA CORPORATION	15.49B		AA
ASCENDIS PHARMA A/S	15.05B	-	-	-	-
EUROFINS SCIENTIFIC SE	14.99B		AA
EXELIXIS, INC.	14.83B		BB
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	14.41B		AA
SUMMIT THERAPEUTICS INC.	14.07B	-	-	-	-
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	13.54B		AA
Average	28.42B		AA
Weighted average by Cap.			AA